Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

PURPOSE: The KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the treatment human epidermal growth factor receptor 2–positive stage II to III breast cancer. T-DM1+P led to a lower pathologic complete respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurvitz, Sara A., Martin, Miguel, Jung, Kyung Hae, Huang, Chiun-Sheng, Harbeck, Nadia, Valero, Vicente, Stroyakovskiy, Daniil, Wildiers, Hans, Campone, Mario, Boileau, Jean-François, Fasching, Peter A., Afenjar, Karen, Spera, Gonzalo, Lopez-Valverde, Vanesa, Song, Chunyan, Trask, Peter, Boulet, Thomas, Sparano, Joseph A., Symmans, W. Fraser, Thompson, Alastair M., Slamon, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
RAPID COMMUNICATION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774816/
https://www.ncbi.nlm.nih.gov/pubmed/31157583
http://dx.doi.org/10.1200/JCO.19.00882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774816/
https://www.ncbi.nlm.nih.gov/pubmed/31157583
http://dx.doi.org/10.1200/JCO.19.00882

Ejemplares similares